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a b s t r a c t
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) show notable effects against
non-small cell lung cancers (NSCLCs) harboring EGFR-activating mutations. However, almost all patients
eventually acquire resistance to EGFR-TKIs. In this study, we established novel erlotinib resistant NSCLC
cells and examined their resistant mechanisms. Resistant cells were established in 14, 3, and 0 wells
exposed to 0.1, 1, and 10M erlotinib, respectively. The IC50 values of these cells were 47- to 1209-fold
higher than that of the parent cells. No secondary T790M mutation was detected in any resistant cells.
However, in 13/17 resistant cells, EGFR copy number was reduced less than approximately one-eighth of
parent cells, and in one resistant cell (B10), >99.99% of the population was EGFR-unampliﬁed cells. Most
(97.5%) parent cells showed EGFR ampliﬁcation, but 2.5% of the population comprised EGFR-unampliﬁedesistance
on-small cell lung cancer
SCLC
cells. An EGFR-unampliﬁed clone (4D8) isolated from parent cells in erlotinib-free normal medium also
showed erlotinib resistance comparable to the resistant B10 cells. Loss of an EGFR-ampliﬁed chromosome
7 (EGFR-ampch7)was observed in 4D8 and B10 cells. EGFR-unampliﬁed cells were constantlymaintained
as a minor population of the parent cells under normal cell culture conditions. In conclusion, loss of
an EGFR-ampch7 causes acquired resistance in EGFR-mutated HCC827 cells exposed to a relatively low
, but
he Aconcentration of erlotinib
© 2013 T
. Introduction
Non-small cell lung cancer (NSCLC) is the most common type
f lung cancer, accounting for approximately 80% of lung cancers.
SCLC is attributed in part to somatic mutations of the epider-
al growth factor receptor gene (EGFR) [1]. The most common
utations are an in-frame E746-A750 deletion in exon 19 and
single-point substitutional L858R mutation in exon 21, both
f which are located in the tyrosine kinase domain of EGFR.
hese two mutations are observed in approximately 90% of EGFR
utations and are termed “activating mutations” [2]. EGFR-TKIs,
uch as geﬁtinib and erlotinib, block autophosphorylation of EGFR
ith subsequent inhibition of the downstream signaling pathwaysnvolving RAS/extracellular signal regulated kinase (ERK)1/2 and
hosphoinositide 3-kinase (PI3K)/AKT, and show favorable activity
n NSCLC patients with activating mutations of EGFR [3]. However,
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almost all patients eventually develop acquired resistance to EGFR-
TKIs within several years [4].
Two genetic mechanisms of acquired resistance to EGFR-TKIs
have been identiﬁed in EGFR-mutated NSCLC. A secondary muta-
tion of T790M in exon 20 of EGFR and ampliﬁcation of the MET
oncogene are observed in approximately 50% and 5% of resistant
cases, respectively [5–8]. Moreover, Yano et al. showed that over-
expression of hepatocyte growth factor (HGF), a ligand for MET,
induces acquired resistance by activatingMET signals [9]. However,
the mechanisms underlying acquired resistance to EGFR-TKIs are
unknown in approximately 30% of EGFR-mutated NSCLC patients
[8]. Further characterization of these unknown mechanisms is
important to develop novel strategies for overcoming acquired
resistance to EGFR-TKIs.
In the present study, we established novel erlotinib-resistant
NSCLC cells with exon 19 deletion of EGFR, and investigated their
acquired resistance mechanisms.
2. Materials and methods
2.1. Cell culture and reagents
Open access under CC BY-NC-ND license.The human NSCLC cell line HCC827 harboring E746-A750
deletion in exon 19 of EGFR was purchased from the American
Type Culture Collection (ATCC, Manassas, VA) and maintained in
-NC-ND license.
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PMI1640 (Sigma-Aldrich Co., Ltd., St. Louis, MO) supplemented
ith10%FBS (JapanBioSerumCo., Ltd., Fukuyama, Japan)at37 ◦C in
% CO2. Erlotinib was provided by F. Hoffman-La Roche Ltd. (Basel,
witzerland) andwas dissolved in DMSO. A single cell was isolated
rom a cell suspension under a light microscope using Picopipet
Altair, Tokyo, Japan) according to the manufacturer’s instructions
nd expanded for further analysis.
.2. Cell proliferation assay
Cells were seeded in 96-well plates and the following day
rlotinib was added at the indicated concentrations. After 4 days,
he viability was determined by crystal violet assay, as described
reviously [10].
.3. Immunoblotting
Immunoblotting was performed as described previously [11].
rieﬂy, cellswere lysed in lysis buffer, and the 20g protein lysates
ere separated on a 7.5% SDS-PAGE gel and then transferred onto
he membrane. Antibodies against EGFR, phospho-EGFR (Y1068),
RK, phospho-ERK, AKT, phospho-AKT (S473) (Cell Signaling Tech-
ology, Inc., Danvers, MA) and -actin (Sigma–Aldrich) were used.
.4. Generation of erlotinib-resistant cells
The 3×102 cells/well were seeded in 96-well plates, and were
ultured in the presence of 0.1, 1, or 10M erlotinib for 3 months.
he resistant cells in eachwellwere isolated andmaintained in cul-
uremedium supplementedwith the corresponding concentration
f erlotinib.
.5. Copy number analysis
Genomic DNA was obtained from the cells using a DNeasy
lood&Tissue kit (QIAGEN, Valencia, CA). Copy numbers of EGFR
nd MET were determined using quantitative real-time PCR anal-
sis with a LightCycler 480 System (Roche Diagnostics, Ltd., Basel,
witzerland) and LightCycler 480 SYBRGreen IMaster (RocheDiag-
ostics) in accordance with the manufacturer’s instructions and
ormalized with ˇ-globin. Human genomic DNA (Promega, Madi-
on, WI) was used as diploid control DNA.
.6. Direct sequencing analysis
PCR primers and sequencing primers for exon 19 and exon 20 of
GFR are listed in Supplementary Table 1. The PCR products were
equenced directly using a BigDye Terminator v3.1 Cycle Sequenc-
ng kit (Life Technologies Co., Ltd., Carlsbad, CA) with an ABI PRISM
100genetic analyzer according to themanufacturer’s instructions.
.7. Melting curve analysis
Melting curve analysis was performed as described previously
12]. In brief, to analyze the E746-A750 mutation status, exon 19
f EGFR was ampliﬁed by PCR from DNA using the appropriate
rimers and the LightCycler 480 Genotyping Master (Roche Diag-
ostics), and then hybridized using sensor and anchor probes. The
rimers and probes are listed in Supplementary Table 1. Plasmids
ontainingwild-type or E746-A750mutation sequenceswere used
s standard DNA..8. HGF expression analysis
cDNA was synthesized by using a CellAmp Direct RNA Prep
it (TAKARA, Shiga, Japan). Real-time RT-PCR was performed tocer 83 (2014) 44–50 45
examine the HGFmRNA expression level using the LightCycler sys-
tem and Applied Biosystems Assay-on-Demand primer probe sets,
Mm00441908m1 (Life Technologies).
2.9. Fluorescence in situ hybridization
Fluorescence in situ hybridization (FISH) for EGFR and the cen-
tromere of chromosome 7 was performed using the VysisTM LSI
EGFR SpectrumOrange/CEP7 SpectrumGreen Probe (Abott, Prince-
ton, NJ) according to themanufacturer’s instructions. This LSI EGFR
probe detects wild-type as well as E746-A750 mutations of EGFR.
To determine the ratio of EGFR-unampliﬁed cells to total cells, 1000
cells were analyzed and counted. Data are shown as the mean of
triplicate replications.
2.10. G-banded chromosome 7 analysis
Karyotypes of chromosome 7 were analyzed using Giemsa
staining of metaphase spreads using standard methods [13].
Chromosomal identiﬁcation and karyotypic designation were per-
formed in accordance with ISCN 2009 guidelines [14].
3. Results
3.1. Exposure to a low concentration of erlotinib generates
erlotinib-resistant HCC827 cells
Erlotinib inhibited HCC827 cell proliferation in a dose-
dependent manner, with the IC50 value of 0.0071M (Fig. 1A).
Erlotinib markedly blocked not only EGFR phosphorylation, but
also ERK and AKT phosphorylation; the downstream kinases of
EGFR signaling cascades (Fig. 1B). To examine the effect of erlotinib
concentrations on the acquisition of resistance, HCC827 cells were
exposed to 0.1, 1, or 10M of erlotinib for 3 months in 96-well
plates, as described in theMaterials andMethods section. Erlotinib-
resistant cells were generated in 14 out of 96 wells by exposure
to 0.1M erlotinib and in 3 out of 96 wells by exposure to 1M
erlotinib (Supplementary Fig. 1A and Table 1). The IC50 values of
the resistant cells were 47- to 1209-fold higher than that of the
parent cells. In addition, the induction of apoptosis by erlotinibwas
markedly decreased compared with that of the parent cells (Sup-
plementary Fig. 1B). No resistant cells appeared in wells exposed
to 10M erlotinib.
Next,we investigated themechanisms bywhich the parent cells
acquired resistance to erlotinib (Table 1). No secondary mutation
of T790M in exon 20 of EGFR or no expression of HGF mRNA was
detected in any of the erlotinib-resistant cells. An approximately
3-fold ampliﬁcation ofMETwasdetected in E10 resistant cells com-
pared with the parent cells. In addition, we found that the parent
cells had 82 copies of EGFR, whereas 13 out of the 17 resistant cells
had less than 10 copies of EGFR.
3.2. EGFR-unampliﬁed clone 4D8 isolated from parent cells in
normal cell culture medium without erlotinib is resistant to
erlotinib
We found that HCC827 parent cells were classiﬁed into two
populations: 97.5% were EGFR-ampliﬁed cells and 2.5% were EGFR-
unampliﬁed cells (Fig. 2A). We next isolated the EGFR-unampliﬁed
clone 4D8 from parent cells cultured in normal medium without
erlotinib by single cell cloning. The clone 4D8 had 3.3 copies of
EGFR and was resistant to erlotinib (IC50: 0.76M) (Fig. 2B and C).
In addition, the levels of expression and phosphorylation of EGFR in
4D8weremarkedly decreased comparedwith the parent cells, and
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he phosphorylation of AKT and ERK was not completely inhibited
ven by treatment with 1M of erlotinib (Figs. 1B and 2D).
.3. Loss of an EGFR-ampliﬁed chromosome 7 (EGFR-ampch7)
ccurs constantly and leads to the emergence of
GFR-unampliﬁed cells in the population of parent cells
Metaphase analysis demonstrated that almost all EGFR-
mpliﬁed parent cells had four chromosome 7 s. Three of them
ontained a single copy of EGFR and the other contained multiple
opies of EGFR (EGFR-ampch7) (Fig. 3A). By G-banded karyotype
nalysis of chromosome 7, we found that the EGFR-ampliﬁed par-
nt cells had four different type of chromosome 7 s (n, a, b and c)
nd clone 4D8 had three different type of chromosome 7 s (n, b,
nd c) (Fig. 3B). Since the chromosome 7 s (n, b and c) other than
GFR-ampch7 (a) were shared with both parent cells and clone
able 1
haracterization of parent cells and erlotinib-resistant cells.
Cells Erlotinib IC50 (M) Exon20 of EGFR
sequence
H
e
Parent cells 0.0071 WT N
0.1M
erlotinib-resistant cells
F5 1.5 WT N
E6 0.47 WT N
A5 0.98 WT N
B10 0.68 WT N
D11 2.0 WT N
E10 7.3 WT N
G1 0.33 WT N
B4 2.0 WT N
G3 0.47 WT N
B7 0.34 WT N
G4 4.0 WT N
G9 0.40 WT N
E9 1.7 WT N
A2 0.51 WT N
1M
erlotinib-resistant cells
A10 1.8 WT N
F9 8.5 WT N
G7 1.8 WT N
ells were evaluated for erlotinib sensitivity, T790M mutational status, HGF mRNA expres
f exon 19, WT: wild-type. Each copy number represents the mean of triplicate assays.ltured in the presence of erlotinib for 4 days, and the proliferation was determined
ts of cell lysates from cells treated with or without erlotinib for 3h.
4D8, it can be considered that clone 4D8 was emerged by loss of
an EGFR-ampch7 in EGFR-ampliﬁed parent cells.
Next, we determined whether the EGFR-unampliﬁed cells
were originally present in the parent cell population and evenly
proliferated as EGFR-ampliﬁed cells, or whether these emerged
constantly as part of the parent cell population under nor-
mal cell culture conditions. For this purpose, we isolated and
expanded two EGFR-ampliﬁed clones, 3B4 and 4F7, from the
parent cells, and found that these clones contain 2.5% and
1.0% of EGFR-unampliﬁed cells, respectively (Fig. 3C and Supple-
mentary Table 2). Furthermore, we isolated two EGFR-ampliﬁed
clones from each of 3B4 and 4F7. These four clones again had
0.6–2.4% of EGFR-unampliﬁed cells (Supplementary Table 2). These
ﬁndings indicate that a small population of EGFR-unampliﬁed cells
emerges constantly in parent cells under normal cell culture con-
ditions (without erlotinib) bymeans of the loss of an EGFR-ampch7
in EGFR-ampliﬁed cells.
GF mRNA
xpression
MET copy number Exon19 of EGFR
sequence
EGFR copy number
.D. 3.9 DEL 82
.D. 2.1 DEL/WT 3.4
.D. 4.8 DEL/WT 6.2
.D. 3 DEL/WT 3.0
.D. 3.8 DEL/WT 3.0
.D. 2.2 DEL/WT 3.1
.D. 13 DEL 52
.D. 3.3 DEL/WT 9.7
.D. 1.9 DEL/WT 2.5
.D. 5.7 DEL/WT 6.5
.D. 2 DEL/WT 3.1
.D. 2.6 DEL 21
.D. 2.1 DEL/WT 3.8
.D. 2.7 DEL/WT 3.6
.D. 2.2 DEL/WT 3.4
.D. 4.3 DEL 54
.D. 3 DEL 67
.D. 3.2 DEL/WT 3.6
sion, and MET and EGFR copy number. N.D.: not detected. DEL: E746-A750 deletion
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Fig. 2. Characteristics of the EGFR-unampliﬁed clone 4D8 isolated from HCC827 parent cells cultured in normal culture medium without erlotinib. (A) FISH analysis of the
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nalysis was performed using quantitative real-time PCR. Each bar represents them
or 4 days was determined by crystal violet assay. Each point represents the mean+
rlotinib for 3h.
.4. Erlotinib-resistant B10 and D11 cell populations were
GFR-unampliﬁed cells
The IC50 values of resistant cells B10 and D11 to erlotinib (0.68
nd 2.0M, respectively) were approximately the same as that of
lone 4D8 (0.76M). The level of expression and phosphorylation
f EGFR in B10 cells were markedly decreased, but the phosphor-
lation of AKT and ERK were not completely inhibited by 1M of
rlotinib (Fig. 4A) aswith clone4D8. Bothof these resistant cells had
hree copies of EGFR, and >99.99% of their populations were clas-
iﬁed as EGFR-unampliﬁed because no EGFR-ampliﬁed cells were
etected in more than 10,000 cells (Fig. 4B, C and Supplementary
ig. 2A and B). By direct sequencing analysis, the parent cells were
hown tohaveonly theE746-A750deletion in exon19, as described
reviously [15], whereas clone 4D8 and B10 and D11 resistant
ells contained both the wild-type and the E746-A750 deletional
equences (Fig. 4D). However, by melting curve analysis, we found
hat approximately 2% of the parent cell population had the wild-
ype allele and 98% had the E746-A750 deletion allele, whereas in
lone 4D8 and B10, D11 resistant cells, approximately 60% of the
opulation had the wild-type allele and 40% had the E746-A750
eletion allele (Fig. 4E).. Discussion
Human NSCLC HCC827 cells have an E746-A750 deletion of
xon 19 and are highly sensitive to EGFR-TKIs. In this study, toies of EGFR (EGFR-unampliﬁed cells; arrow) in parent cells. (B) EGFR copy number
D of triplicates. (C) Proliferation of parent cells and clone 4D8 treatedwith erlotinib
triplicates. (D) Immunoblots of cell lysates from clone 4D8 treated with or without
examine novel mechanisms of acquired resistance to EGFR-TKIs,
erlotinib-resistant cells were established by continuously expos-
ing HCC827 cells to 0.1, 1, or 10M of erlotinib. Since clinically
applicable erlotinib doses, 25, 100, or 150mg, lead to maximum
plasma concentrations of 0.8, 1.9, and 5.6M, respectively [16,17],
the exposure concentrations were selected to cover the achievable
plasma concentrations of erlotinib (0.8–5.6M) in examining the
relationship between concentration and resistance acquisition to
erlotinib. Erlotinib inhibited the generation of resistant cells in a
dose-dependent manner. Resistant cells were generated by expo-
sure to 0.1 and 1M of erlotinib in 14/96 wells and 3/96 wells,
respectively. No resistant cells appeared inwells exposed to 10M
erlotinib. These results suggest that, to prevent acquired resistance
to erlotinib, it is important to keep the plasma concentration as
highaspossibleby treatingpatientswith thehighest recommended
dose (150mg) of erlotinib as far as it can be tolerated.
We found that 17 resistant cells obtained were classiﬁed into
three groups based on the change in MET or EGFR copy number
compared with the parent cells: (1) cells having more than 3-fold
increase in MET copy number, (2) cells having nearly-unchanged
MET and EGFR copy numbers, (3) cells having less than a half
decrease in EGFR copy number. The ﬁrst group included one resis-
tant cell (E10) having more than 3-fold increase in MET copy
number. Engelman et al. reported that HCC827 cells developed
resistance to geﬁtinib in vitro as a result of focal ampliﬁcation of
MET in all six clones isolated [7]. The discrepancy in the incidence
of MET ampliﬁed cells between our study (1/17) and Engelman’s
48 K. Furugaki et al. / Lung Cancer 83 (2014) 44–50
Fig. 3. Loss of an EGFR-ampch7 in EGFR-ampliﬁed cells. (A) Metaphase FISH analysis of the EGFR/CEP7 probe set. EGFR-ampliﬁed cells had an EGFR-ampch7 (arrow). (B)
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ISH analysis of the EGFR/CEP7 probe set of clone 3B4 isolated from EGFR-ampliﬁed
tudy (6/6) may be caused by the different methods for generating
esistant cells. In Engelman’s study cells were exposed to stepwise-
ncreased concentration (0.001–0.1M) of geﬁtinib. In contrast,
ur method, exposing cells to ﬁxed concentrations of erlotinib (0.1
r 1.0M), is considered to better mimic clinical settings because
atients are constantly treated with the recommended dose of an
GFR-TKI during the therapy.
The second group included 2 resistant cells (A10 and F9). The
ET and EGFR copy numbers of these cells were the closest to the
arent cells in the three groups. No secondary mutation of T790M,
GF mRNA over-expression, or KRAS mutations were detected in
hese cells (data not shown). Thus, we did not identify the resis-
ance mechanism in this group so far. Further studies are needed
o elucidate the mechanism associated with resistance. Several
nown mechanisms such as insulin-like growth factor I recep-
or (IGF1R) expression, HER2/HER3 expression, PIK3CA mutations,
pithelial–mesenchymal transition (EMT), and small cell lung can-
er (SCLC) transformation [8,18] may be candidates.
The third group included 14 resistant cells (other than E10,
10, and F9). We proposed a model for the acquired resistance to
rlotinib in this group (Fig. 5). Even in usual culture conditionwith-
ut erlotinib, HCC827 parent cellsmaintain EGFR-unampliﬁed cells
y a constant fraction. These cells were generated by the loss of an
GFR-ampch7 in EGFR-ampliﬁed cells. The levels of expression and
hosphorylation of EGFR in EGFR-unampliﬁed cells, such as clone
D8 and resistant cell B10, were drastically decreased compared
ith theparent cells,whereas thedownstreamAKT/ERKphosphor-
lationwasnotdecreased (Supplementary Fig. 3).Whenexposed to
elatively low concentrations of erlotinib (0.1 and 1M), the resis-
ant cells, namely, thepre-existing EGFR-unampliﬁed cells survived
nd proliferated in the parent cell population (Fig. 5).2); b and c, add(7) (q11.2) with different additional material of unknown origin. (C)
t cells. A subset (2.5%) of cells was EGFR-unampliﬁed cells (arrow).
Whether this phenomenon can be found in other cell lines is of
interest.We found that EGFR exon 19 deleted NSCLC cell line B901L
has two EGFR-ampch7 and has pre-existing EGFR-unampliﬁed cells
(about 0.2%) under normal culture conditions (Supplementary
Fig. 4). Although the mechanism associated with the loss of an
EGFR-ampch7 with exon 19 deletion in EGFR-ampliﬁed cells under
normal culture conditions is unclear, themutationofEGFR andmul-
tiple centromeres in EGFR-ampch7 may cause genetic instability.
Copy number gains and mutant allele-speciﬁc imbalances such as
ampliﬁcation, polysomy, or uniparental disomy, occur frequently
in tumor cells with EGFR mutations [19]. In ﬁssion yeast, abnormal
centromere function results in a highly elevated rate of chromo-
some loss and chromosome missegregation [20]. Furthermore, the
proportion of EGFR-unampliﬁed cells in the parent cell population
was unchanged for 9 months under normal cell culture conditions
(2.5% at the start and 2.1% after 9 months; data not shown). These
ﬁndings indicate that the abnormality of the EGFR-ampch7 may
lead to uneven distribution of the chromosome during mitosis not
frequently but constantly.
Although we did not identify the novel addicted oncogene
in EGFR-unampliﬁed resistant cells (4D8, B10 or D11), wild-type
EGFR may be a candidate because the proliferation of these cells
was still inhibited by more than approximately 1M of erlotinib
(Supplementary Fig. 5A). In addition, the erlotinib of corresponding
concentration completely blocks the phosphorylation of wild-type
EGFR [21]. Furthermore, the IC50 value of irreversible EGFR-TKI,
afatinib, to 4D8 and D11 cells was approximately 25-fold higher
than that of the parent cells (Supplementary Fig. 5B). In addition,
EGFR knockdown by siRNA partially but signiﬁcantly inhibited cell
proliferation in all of three resistant cells (Supplementary Fig. 5 C).
These results indicate that EGFR-unampliﬁed resistant cells could
K. Furugaki et al. / Lung Cancer 83 (2014) 44–50 49
Fig. 4. Characteristics of the erlotinib-resistant B10 and D11 cell populations. (A) Immunoblots of cell lysates from erlotinib-resistant B10 cells treated with or without
erlotinib for 3h. (B and C) FISH analysis of the EGFR/CEP7 probe set of control (B) and metaphase spreads (C). EGFR, red; CEP7, green. (D) Direct sequencing analysis of EGFR
exon 19. The underlined sequences of the 4D8 clone, and the B10 and D11 cells contained both the E746-A750 deletion and the wild-type alleles. (E) Melting curve analysis
of standard deletion/wild-type plasmids and DNA from cells. Left peaks indicate the wild-type EGFR (arrow). The wild-type peaks of the parent cells and the 4D8 clone and
B10 and D11 cells were nearly identical to those of the 2% and 60% wild-type/E746-A750 deletion plasmids, respectively.
Low concentration 
of EGFR-TKIs
Without EGFR-TKIs
Not acquired resistant cells
Parent cells
EGFR wild-type 
EGFR-TKIs resistant cells
Amplified EGFR exon 19 deletion
EGFR exon 19 deletion 
Fig. 5. Model for acquired resistance to EGFR-TKIs in EGFR-mutated HCC827 cells. A small population of EGFR-unampliﬁed cells is constantly maintained in the parent
cell population by the loss of an EGFR-ampch7 with exon 19 deletion in EGFR-ampliﬁed cells under normal cell culture conditions in HCC827 cells (without EGFR-TKIs).
Resistant cells are generated by pre-existing EGFR-unampliﬁed cells being selected at low concentrations of EGFR-TKIs. High concentrations of EGFR-TKIs completely inhibit
the proliferation of not only EGFR-ampliﬁed cells, but also EGFR-unampliﬁed cells. EGFR-ampliﬁed cells have three types of chromosome 7 s; approximately 80 copies of exon
19 deletion EGFR (EGFR-ampch7), single-copy of exon 19 deletion EGFR and wild-type EGFR. EGFR-unampliﬁed cells have two types of chromosome 7 s; single-copy of exon
19 deletion EGFR and wild-type EGFR.
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avorably change the addiction from delE746-A750 EGFR to the
thergrowthdrivers includingwild-typeEGFReven in thepresence
f one or two copies of delE746-A750 EGFR. HER family receptor
inases may be another candidates. Tabara et al. have shown that
omplete loss of the activating EGFR mutant gene results in the
ain of a novel addiction to HER2/HER3 signaling and the acquisi-
ion of EGFR-TKI resistance in vitro [22]. In our resistant cells (4D8
nd B10), cell proliferation was partially blocked by HER2 or HER3
nockdown (Supplementary Fig. 6). Theseﬁndings indicate that the
GFR-unampliﬁed resistant cells partially depend on not only EGFR
ut also HER2/HER3 signaling for survival.
Compared with other solid tumors, NSCLC is well known for
he heterogeneity of the cell populations in individual lesions
23]. Heterogeneous distribution of EGFR mutations in individual
umors has also been reported [24–26]. In addition, loss of an EGFR
utation is reported in 3 out of 11 EGFR-mutated NSCLC patients
ith progressive disease after geﬁtinib treatment [22]. These ﬁnd-
ngs indicate that some NSCLCs are genetically heterogeneous and
oncurrently have tumor cell populations with either mutant or
ild-typeEGFR, and that theEGFRgeneticheterogeneitymight con-
ribute to acquired resistance to EGFR-TKIs. Our results strongly
upport this mechanism of resistance, because we have clearly
hown that the genetic heterogeneity of EGFR is constantly main-
ained by the loss of an EGFR-ampch7 in NSCLC cells with EGFR
utations.
In conclusion, we demonstrated that loss of ampliﬁed EGFR-
utated genes causes acquired resistance in HCC827 cells when
he cells are exposed to a relatively low concentration of erlotinib,
hereas high concentration of erlotinib prevents the emergence of
esistance. In addition to themajor knownmechanisms of acquired
esistance to EGFR-TKIs, including secondary mutation of T790M,
mpliﬁcationofMET,mutationsofPIK3CA, EMT, and transformation
o SCLC [8], our ﬁndings propose a novel acquired resistant mecha-
ism, namely, the selection of preexisting EGFR-unampliﬁed cells,
hicharegeneratedby the lossof anampliﬁedEGFR-mutatedgene,
ay contribute to the acquired resistance to EGFR-TKIs. Further
tudies are needed to identify alternative addictive signal path-
ay(s) after the loss of ampliﬁed EGFR with mutation and to lead
o the development of a novel molecular targeted therapy against
GFR-TKI-refractory NSCLC.
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